Ionis Pharmaceuticals INC (IONS) — 8-K Filings

All 8-K filings from Ionis Pharmaceuticals INC. Browse 26 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (26)

Ionis Pharmaceuticals Files 8-K on Agreements and Equity Sales — Nov 17, 2025 Risk: medium
On November 11, 2025, Ionis Pharmaceuticals, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reporte
Ionis Pharmaceuticals Files 8-K — Nov 10, 2025 Risk: low
On November 8, 2025, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns other events and regulation FD disclosures, with no specific
Ionis Pharmaceuticals Files 8-K on Financials — Oct 29, 2025 Risk: low
Ionis Pharmaceuticals, Inc. filed an 8-K on October 29, 2025, reporting on its results of operations and financial condition. The filing includes financial stat
Ionis Pharmaceuticals Files 8-K — Sep 22, 2025 Risk: low
Ionis Pharmaceuticals, Inc. filed an 8-K on September 22, 2025, reporting on other events and financial statements. The filing does not contain specific financi
Ionis Pharmaceuticals Files 8-K Report — Sep 2, 2025 Risk: low
On September 2, 2025, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and other events, indica
Ionis Pharmaceuticals Files 8-K Report — Aug 21, 2025 Risk: low
On August 21, 2025, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events an
Ionis Pharmaceuticals Files 8-K on Financials — Jul 30, 2025 Risk: low
Ionis Pharmaceuticals, Inc. filed an 8-K on July 30, 2025, reporting on its results of operations and financial condition. The filing includes financial stateme
Ionis Pharmaceuticals Files 8-K on Director Changes and Compensation — Jun 12, 2025 Risk: low
On June 12, 2025, Ionis Pharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filin
Ionis Pharmaceuticals Files 8-K on Shareholder Votes & Financials — Jun 10, 2025 Risk: low
Ionis Pharmaceuticals, Inc. filed an 8-K on June 10, 2025, reporting on matters submitted to a vote of security holders and financial statements as of June 5, 2
Ionis Pharmaceuticals Files 8-K Report — May 19, 2025 Risk: low
On May 19, 2025, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific
Ionis Pharmaceuticals Files 8-K — Apr 30, 2025 Risk: low
Ionis Pharmaceuticals, Inc. filed an 8-K on April 30, 2025, reporting on its results of operations and financial condition, and including financial statements a
Ionis Pharmaceuticals Files 8-K for Material Agreement — Mar 12, 2025 Risk: medium
On March 11, 2025, Ionis Pharmaceuticals, Inc. filed an 8-K report to disclose the entry into a material definitive agreement. The filing does not provide speci
Ionis Pharmaceuticals Files 8-K on Operations and Financials — Feb 19, 2025 Risk: low
On February 19, 2025, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition
Ionis Pharmaceuticals Files 8-K — Dec 20, 2024 Risk: low
Ionis Pharmaceuticals, Inc. filed an 8-K on December 20, 2024, reporting an event that occurred on December 19, 2024. The filing is related to "Other Events" an
Ionis Pharmaceuticals Files 8-K on Financials — Nov 6, 2024 Risk: low
On November 6, 2024, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition,
Ionis Pharmaceuticals Files 8-K Report — Sep 12, 2024 Risk: low
On September 9, 2024, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," ind
Ionis Pharmaceuticals Files 8-K Report — Sep 9, 2024 Risk: low
On September 9, 2024, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and does not detail specific new transaction
Ionis Pharmaceuticals Files 8-K — Aug 1, 2024 Risk: low
Ionis Pharmaceuticals, Inc. filed an 8-K on August 1, 2024, reporting on its results of operations and financial condition. The filing includes financial statem
Ionis Pharmaceuticals Files 8-K Report — Jun 18, 2024 Risk: low
On June 18, 2024, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the entry into a material definitive agreement and the submissi
Ionis Pharmaceuticals Files 8-K on Shareholder Votes and Exhibits — Jun 10, 2024 Risk: low
Ionis Pharmaceuticals, Inc. filed an 8-K on June 10, 2024, reporting on matters submitted to a vote of security holders and financial statements/exhibits. The e
Ionis Pharmaceuticals Files 8-K — May 31, 2024 Risk: low
Ionis Pharmaceuticals, Inc. filed an 8-K on May 31, 2024, to report other events and financial statements. The filing does not contain specific details about ne
Ionis Pharmaceuticals Files 8-K on Operations — May 7, 2024 Risk: low
On May 7, 2024, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as w
Ionis Pharmaceuticals Files 8-K Report — Apr 8, 2024 Risk: low
On April 7, 2024, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material ev
Ionis Pharma Enters Material Agreement, Adjusts Officer Compensation — Feb 29, 2024 Risk: medium
Ionis Pharmaceuticals, Inc. filed an 8-K on February 29, 2024, reporting an event on February 28, 2024, concerning an entry into a material definitive agreement
Ionis Pharma Files 8-K on Financial Condition — Feb 21, 2024 Risk: low
Ionis Pharmaceuticals Inc. filed an 8-K on February 21, 2024, to report on its results of operations and financial condition. The filing, under SEC File Number
Ionis Pharma Signals Major Corporate Event via 8-K Filing — Jan 22, 2024
Ionis Pharmaceuticals, Inc. filed an 8-K on January 22, 2024, indicating that it is using written communications under Rule 425 of the Securities Act, solicitin

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX